Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis

Journal article


Publication Details

Author(s): Vermersch P, Martinelli V, Pfleger C, Rieckmann P, Alonso-Magdalena L, Galazka A, Dangond F, Phillips L
Journal: Clinical Therapeutics
Publication year: 2019
Volume: 41
Journal issue: 2
Pages range: 249-260
ISSN: 0149-2918


Abstract

Purpose: We applied Multi-Criteria Decision Analysis (MCDA) methods in a structured benefit-risk assessment of cladribine and newer approved disease-modifying drugs (DMDs) for patients with relapsing-remitting multiple sclerosis (RRMS).


Additional Organisation
Neurologische Klinik


External institutions with authors

Aalborg University
EMD Serono
LILLE 1 University - Science and Technology
Medical Park Loipl
Merck Sharp & Dohme Corp
Ospedale San Raffaele (früher: Centro San Raffaele del Monte Tabor Foundation)
Skåne University Hospital / Skånes universitetssjukhus
The London School of Economics and Political Science


How to cite

APA:
Vermersch, P., Martinelli, V., Pfleger, C., Rieckmann, P., Alonso-Magdalena, L., Galazka, A.,... Phillips, L. (2019). Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis. Clinical Therapeutics, 41(2), 249-260. https://dx.doi.org/10.1016/j.clinthera.2018.12.015

MLA:
Vermersch, Patrick, et al. "Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis." Clinical Therapeutics 41.2 (2019): 249-260.

BibTeX: 

Last updated on 2019-08-04 at 09:24